Read the ASGCT-Citeline 2024 Q3 Landscape Analysis Field Report

Read + download the full report - October 24, 2024

In Q3, Tecelra was approved for adults with metastatic synovial sarcoma, newly initiated gene therapy trials increased for non-oncology indications, and seed and Series A funding nearly doubled.

The third quarterly report of 2024 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Highlights from this issue include:

  • Tecelra became the first gene therapy approved for adults with metastatic synovial sarcoma and the first FDA-approved T cell receptor (TCR) gene therapy

  • The field steadily diversified, with data showing 51% of newly initiated gene therapy trials are for non-oncology indications, up from 39% year-over-year

  • Seed and Series A funding nearly doubled to $484 million

Download the full report


Click any of the samples below to view the full report: